SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom's strong Q1 earnings, significantly raised guidance for AI revenue, and new partnerships with major AI players like OpenAI are fueling conversation. While many celebrate these "grand slam" results and long-term projections, a notable community discussion centers on the stock's initial muted after-hours reaction and whether it will sustain gains or follow the pattern of other big tech post-earnings sell-offs.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending following its latest earnings report, which showcased robust revenue and user growth but drew mixed community reactions regarding its diluted profitability figures and ongoing stock dilution. Bulls emphasize the platform's expanding market share and customer assets, while bears voice frustration over management's perceived inaction in translating operational success into shareholder value.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending after reporting lower-than-expected revenue in its Q4 earnings, fueling a polarized community discussion. While bears label the stock a "quantum scam" given its high valuation against minimal sales, bulls point to a robust cash position, the achievement of 99.9% gate fidelity, and recent system orders as strong indicators of its long-term potential in the nascent quantum technology sector.

Amprius Technologies, Inc. engages in the development, manufacture, and market lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the United States and Rest of the World geographical segments. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending following its robust earnings report, which highlighted significant revenue and adjusted EPS beats, positive full-year guidance, and a strategic U.S. manufacturing partnership for its high-performance silicon batteries. The community is actively discussing the company's progress towards profitability and its strengthened position for defense contracts and NDAA compliance within the rapidly expanding drone and eVTOL markets, despite a notable one-time charge affecting net results.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending, fueled by imminent Phase 3 results for its AML immunotherapy, GPS, and amid widespread expectations of a significant buyout. The reported extended survival of trial patients, combined with management's silence, is intensifying buyout rumors and the potential for a short squeeze, propelling community discussion about its massive undervalued potential.

Okta, Inc. engages in the provision of an identity management platform for enterprises. It operates through the United States and International geographical segments. The firm's products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Okta is trending after reporting strong current quarter results but issuing forward guidance that fell below analyst expectations, signaling its first projected single-digit revenue growth since IPO. This outlook has fueled investor debate, with some expressing caution about decelerating enterprise spending, while others emphasize the company's solid performance and its long-term opportunity in securing AI agents amid wider cybersecurity sector re-evaluations.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem is actively discussed following its strategic decision to discontinue the RAMP 203 trial, prioritizing the VS-7375 KRAS G12D inhibitor and its robust 69% response rate, alongside a solid preliminary Q4 revenue report. While some investors see this pipeline focus and increasing institutional interest as a long-term positive, many express frustration over the stock's persistent decline and its underperformance relative to other trending RAS-targeting biotechs.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as investors weigh its appeal as a safe-haven asset amidst escalating Middle East tensions, while simultaneously navigating the uncertainty of persistent inflation signals and shifting expectations for Federal Reserve policy.

Veeva Systems, Inc. engages in the provision of industry cloud solutions for the global life sciences industry. Its solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance. The firm's customer relationship management solutions enable its customers to increase the productivity and compliance of their sales and marketing functions. Its regulated content management and collaboration solutions enable its customers to more efficiently manage regulated, content-centric processes across the enterprise. The company's customer master solution enables customers to more effectively manage complex healthcare provider and healthcare organization data. The company was founded by Mark Armenante, Peter P. Gassner, Doug Ostler, Mitch Wallace and Matthew J. Wallach on January 12, 2007, and is headquartered in Pleasanton, CA.

Veeva Systems Inc - Ordinary Shares - Class A

Veeva Systems is trending after reporting strong financial results and optimistic guidance, fueling community discussion around its AI advancements and the prospect of a stock split to broaden investor access. The market is largely optimistic about its continued growth in the mission-critical life sciences sector.

Stem, Inc. engages in the provision of an energy storage system, hardware, ongoing software platform and professional services, and solar asset performance monitoring and control. The company was founded in 2009 and is headquartered in Houston, TX.

Stem Inc - Ordinary Shares - Class A

Stem Inc

Stem Inc. is trending following its earnings report, which presented the company's first positive adjusted EBITDA, a point of optimism for those noting cost cuts and a software pivot. However, community discussions are divided, with many highlighting flat guidance for 2026, continued underlying losses, and significant debt as major concerns for the energy storage software firm.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The rumors originated after Day One featured on the Betaville blog which highlights potential corporate transactions.</li><li>Brisbane, California-based Day One is focused on developing therapies for life-threatening diseases including pediatric cancer.</li><li>According to data from Koyfin, eight of the nine analysts covering DAWN stock rate it ‘Buy’ or higher, while one rates it a ‘Hold.’</li></ul>Shares of Day One Biopharmaceuticals (DAWN) garnered retail attention on Wednesday amid speculation regarding a potential merger or acquisition deal.On Stocktwits, retail sentiment around DAWN stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed hopes for a buyout but noted that it could be days or weeks away.<stembedurl>https://www.stocktwits.com/flyingt333/message/646600838</stembedurl>Another user noted that the stock is showing relative strength compared to the market. “That’s a bullish sign,” they wrote.<stembedurl>https://www.stocktwits.com/topstockalerts/message/646598772</stembedurl>Yet another, however, noted that there was a similar rumor on a buyout for Seres Therapeutics (MCRB) from Nestlé Health Science which has not materialised.<stembedurl>https://www.stocktwits.com/Steve_TheBull_Rogers/message/646596366</stembedurl>Shares of the company closed 28% higher over the deal speculation.<h2 class="st-heading-2">Rumor Origin</h2>The rumors originated after Day One featured on the Betaville blog which highlights potential corporate transactions. The blog highlights that the news is market gossip and added that it might be “total codswallop.”Brisbane, California-based Day One is focused on developing therapies for life-threatening diseases including pediatric cancer. Its pipeline includes Ojemda, DAY301 and Emi-Le.In 2025, the company reported product revenue of $155.4 million from Ojemda. The company now expects U.S. revenue of $225 million to $250 million for Ojemda in 2026.The company reported a net loss of $107.3 million for full year 2025, compared to loss of $95.5 million for full year 2024.<h2 class="st-heading-2">Analyst Take</h2>According to data from Koyfin, eight of the nine analysts covering<a href="https://stocktwits.com/symbol/DAWN"> DAWN stock </a>rate it ‘Buy’ or higher, while one rates it a ‘Hold.’The average price target on the stock is $22.75, representing a potential upside of over 75% from current trading levels.Shares of the company have gained about 50% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fed-beige-book-notes-modest-price-increase-across-districts/cZd9xkURIda">Fed Beige Book Notes Modest Price Increase Across Districts In Recent Weeks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Day One Biopharmaceuticals logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

DAWN Shares Rally On Buyout Speculation But Retail Warns A Deal Might Not Materialise

On Stocktwits, retail sentiment around DAWN stock stayed within the ‘extremely bullish’ territory over the past 24 hours.

Equity

Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 26.2% - What's Next?

Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 26.2% - Here's Why...

Research Analysts Issue Forecasts for DAWN Q1 Earnings

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Stock analysts at HC Wainwright decreased their Q1 2026 EPS estimates for Day One Biopharmaceuticals in a research report issued to...

Day One Biopharmaceuticals (NASDAQ:DAWN) Rating Lowered to Hold at Zacks Research

Zacks Research downgraded Day One Biopharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday...

Day One Biopharmaceuticals (NASDAQ:DAWN) Announces Earnings Results, Misses Expectations By $0.04 EPS

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of...

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down After Earnings Miss

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down on Disappointing Earnings...

Wedbush Forecasts Strong Price Appreciation for Day One Biopharmaceuticals (NASDAQ:DAWN) Stock

Wedbush raised their price objective on shares of Day One Biopharmaceuticals from $29.00 to $30.00 and gave the stock an "outperform" rating in a research report on Wednesday...

Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Lowered to $22.00 at HC Wainwright

HC Wainwright dropped their price objective on Day One Biopharmaceuticals from $25.00 to $22.00 and set a "buy" rating for the company in a report on Wednesday...

Needham & Company LLC Lowers Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $17.00

Needham & Company LLC lowered their price target on shares of Day One Biopharmaceuticals from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday...

Day One Biopharmaceuticals Q4 Earnings Call Highlights

Day One Biopharmaceuticals (NASDAQ:DAWN) detailed accelerating commercial momentum for OJEMDA and outlined several upcoming clinical catalysts during its fourth-quarter and full-year 2025 earnings...

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

Day One Biopharmaceuticals Inc

Software / SaaS

Cybersecurity

Cloud Infrastructure

AI / Semiconductors

Which beaten-down sector are you buying first?

Stocktwits

Stocktwits Polls

Heavy speculation surrounds a potential acquisition of DAWN, with various suitors like Jazz Pharmaceuticals and Ipsen rumored, and price targets ranging from $15-$40 per share.

Shares are experiencing significant rallies and increased trading volume, with many noting strong relative strength and anticipation of further upside movement.

Discussions highlight DAWN's robust pipeline, including OJEMDA's strong revenue growth and the acquired Emile (ADC drug) showing blockbuster potential, bolstering long-term value.

Users are expressing dissatisfaction with management's decisions, citing issues like option repricing and perceived lack of communication regarding company news and shareholder value.

DAWN
Day One Biopharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DAWN News

DAWNDay One Biopharmaceuticals Inc